CD8A and neoplasm: Since improved identification of anti-tumour T cells is crucial for advancing cancer immunotherapies, the anticipated efficacy of pleural CD39 + CD8 + T cell-based immunotherapy could be attributed to both their cytolytic activity and their tumour-reactive characteristics [30].